Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluconazole, quantity: 50 mg - capsule, hard - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; silicon dioxide; magnesium stearate; maize starch; titanium dioxide; potable water; gelatin; brilliant scarlet 4r; patent blue v; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggests that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of acute phase cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal canidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oesophageal canidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks. (see adverse reactions).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluconazole, quantity: 150 mg - capsule, hard - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; silicon dioxide; magnesium stearate; maize starch; titanium dioxide; potable water; gelatin; propylene glycol; purified water; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; potassium hydroxide; iron oxide black - treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggests that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of acute phase cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal canidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oesophageal canidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea crur

Сингапур - Енглески - HSA (Health Sciences Authority)

gilead sciences singapore pte. ltd. - amphotericin b - injection, powder, for solution - 50 mg/vial - amphotericin b 50 mg/vial

Малта - Енглески - Malta Medicines Authority

gilead sciences international limited - amphotericin b 50 mg - powder for concentrate for dispersion for infusion

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences ltd - amphotericin b - powder for solution for injection - 50mg

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

cambridge laboratories ltd - amphotericin b - powder for solution for injection - 50mg

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

beacon pharmaceuticals ltd - amphotericin b - powder for solution for infusion - 50mg

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences ltd - amphotericin b - powder for solution for infusion - 50mg

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

beacon pharmaceuticals ltd - amphotericin b sodium cholesteryl sulfate complex - powder for solution for infusion - 50mg

Саудијска Арабија - Енглески - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

gilead sciences limited (cork), ireland - amphotericin b - powder for concentrate for dispersion for infusion - 50 mg